LeonaBio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $72.4M
- Price
- $7.68
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.19%
- Volume
- 9.7K
About
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Quick stats
Shares outstanding9.4M
Computed float5.8M
Float / shares61.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001620463
Websitehttps://leonabio.com
AI Summary
AI-generated1/8
majorbullishearnings
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
LeonaBio reported Q2 financials, reaffirming its timeline for the pivotal Phase 3 ELAINE-3 trial of lasofoxifene, which is on track to complete enrollment in 4Q 2026 with topline data expected in 2H 2027.
The company ended the quarter with $51.1 million in cash and investments, after using $37.9 million in operations for the quarter, and retains access to up to an additional $146 million via warrants.
R&D expenses increased to $12.9 million, driven by the ELAINE-3 trial, while the net loss was $19.0 million, or $0.80 per share.